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Islet transplantation for the treatment of type 1 diabetes mellitus is limited in its clinical application mainly 
due to early loss of the transplanted islets, resulting in low transplantation efficiency. NKT cell–dependent 
IFN-γ production by Gr-1+CD11b+ cells is essential for this loss, but the upstream events in the process remain 
undetermined. Here, we have demonstrated that high-mobility group box 1 (HMGB1) plays a crucial role in 
the initial events of early loss of transplanted islets in a mouse model of diabetes. Pancreatic islets contained 
abundant HMGB1, which was released into the circulation soon after islet transplantation into the liver. Treat-
ment with an HMGB1-specific antibody prevented the early islet graft loss and inhibited IFN-γ production 
by NKT cells and Gr-1+CD11b+ cells. Moreover, mice lacking either of the known HMGB1 receptors TLR2 or 
receptor for advanced glycation end products (RAGE), but not the known HMGB1 receptor TLR4, failed to 
exhibit early islet graft loss. Mechanistically, HMGB1 stimulated hepatic mononuclear cells (MNCs) in vivo 
and in vitro; in particular, it upregulated CD40 expression and enhanced IL-12 production by DCs, leading to 
NKT cell activation and subsequent NKT cell–dependent augmented IFN-γ production by Gr-1+CD11b+ cells. 
Thus, treatment with either IL-12– or CD40L-specific antibody prevented the early islet graft loss. These find-
ings indicate that the HMGB1-mediated pathway eliciting early islet loss is a potential target for intervention 
to improve the efficiency of islet transplantation.
????????????
Pancreatic islet transplantation, although an attractive procedure 
for the treatment of type 1 diabetes mellitus, usually fails to achieve 
insulin independence of a diabetic recipient from a single donor due 
to early loss of transplanted islets and therefore requires sequential 
transplantations of islets with the use of 2–3 donors (1). Thus, the 
low efficiency of islet transplantation has been a major obstacle fac-
ing islet transplantation and hampers its clinical application.
We have previously shown in mice that loss of transplanted islets 
soon after transplantation is caused by NKT cell–dependent IFN-γ 
production by Gr-1+CD11b+ cells and is successfully prevented by 
treatment of NKT cells with repeated stimulation with their syn-
thetic ligand, α-galactosylceramide (α-GalCer), to downregulate 
IFN-γ production of NKT cells, or by depletion of Gr-1+CD11b+ cells 
with anti–Gr-1 antibody (2). However, precisely how it is involved in 
the upstream events in the activation of NKT cells and Gr-1+CD11b+ 
cells in the early loss of transplanted islets remains to be solved.
High-mobility group box 1 (HMGB1) protein was initially 
found to be a DNA-binding protein present in almost all eukary-
otic cells, where it stabilizes nucleosome formation and acts as 
a nuclear factor that enhances transcription (3, 4). Recently, 
HMGB1 has been demonstrated to play crucial roles in response 
to tissue damage, indicating that HMGB1 is a prototype of the 
emerging damage-associated molecular pattern molecule (4, 
5). HMGB1 is also known to be secreted by activated immune 
cells, including macrophages (6, 7), DCs (8), and NK cells (9) in 
response to infection and inflammatory stimuli. Once secreted, 
HMGB1 induces inflammatory responses by transduction of cel-
lular signals through its receptors, such as TLR2, TLR4 (10–12), 
and receptor for advanced glycation end products (RAGE) (8, 
13, 14). Moreover, HMGB1 levels are markedly increased during 
severe sepsis in humans and animals, and administration of neu-
tralizing HMGB1-specific antibodies prevents lethality from sep-
sis (6). Recent accumulating evidence now suggests that HMGB1 
acquires or augments proinflammatory activity by binding to 
proinflammatory mediators such as LPS, IL-1 (14), and DNA 
(15–17). These observations indicate that HMGB1 is an essential 
mediator of organ damage; however, its precise role and mecha-
nism remain unknown. Here, we investigate the mechanisms of 
action of HMGB1 in the early loss of transplanted islets.
???????
Involvement of HMGB1 in early loss of transplanted islets. It has previ-
ously been shown that hyperglycemia of streptozotocin-induced 
(STZ-induced) diabetic recipient mice was ameliorated after trans-
plantation of 400 syngenic islets in the liver but not of 200 islets 
(Figure 1A, no treatment), the number of islets isolated from a 
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single mouse pancreas (2). By using the diabetes model mice, we 
first investigated the effects of anti-HMGB1 antibody to examine 
whether HMGB1 is directly involved in early loss of transplanted 
islets. STZ-induced diabetic mice that received 200 islets together 
with anti-HMGB1 antibody once at the time of islet transplan-
tation became normoglycemic, in contrast to mice treated with 
control chicken IgG (Figure 1A). The results demonstrated that 
the anti-HMGB1 antibody ameliorates hyperglycemia of diabetic 
mice, indicating that the early loss of transplanted islets is pre-
vented by anti-HMGB1. Thus, HMGB1 plays a crucial role in early 
loss of transplanted islets.
IFN-γ production of NKT cells and Gr-1+CD11b+ cells in the liver receiv-
ing islets is inhibited by anti-HMGB1 antibody. Next, we determined 
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production by NKT cells and Gr-1+CD11b+ cells in the liver of 
mice receiving islets, which are essential components of early loss 
of transplanted islets, as shown previously (2). For those purposes, 
mononuclear cells (MNCs) in the liver of recipient mice were isolat-
ed at 6 hours after islet transplantation of 200 syngenic islets into 
the liver and examined by FACS as to IFN-γ production by NKT 
cells and Gr-1+CD11b+ cells in the liver. The results are in agreement 
with the previous findings (2) that, within 6 hours after transplan-
tation of syngeneic islets into the liver, NKT cells and Gr-1+CD11b+ 
cells accumulated into the liver with upregulated production of 
IFN-γ (Figure 1B). This upregulated production of IFN-γ after 
islet transplantation was inhibited by anti-HMGB1. Since the 
treatment with anti-HMGB1 antibody did not affect the number 
of infiltrated Gr-1+CD11b+ cells (Figure 1B), the recruitment of 
Gr-1+CD11b+ cells was due not to HMGB1, but rather probably 
to the events of transplantation itself. These findings suggest that 
HMGB1 is essentially involved in the activation of NKT cells and/or 
Gr-1+CD11b+ cells in the liver after islet transplantation.
NKT cell–dependent IFN-γ production by Gr-1+CD11b+ cells upon stim-
ulation with HMGB1. In order to confirm HMGB1-dependent IFN-γ 
production, we investigated whether HMGB1 has any stimulatory 
effects in vivo on NKT cells and/or Gr-1+CD11b+ cells in the liver 
of mice (Figure 1C). For those purposes, HMGB1 was adminis-
tered i.v. into naive wild-type and NKT cell–deficient Jα18–/– mice, 
and their hepatic MNCs were isolated at 2 hours after the injec-
tion and examined by flow cytometry. It was found that IFN-γ 
production was upregulated in NKT cells and Gr-1+CD11b+ cells 
in the liver of wild-type mice treated with HMGB1 (Figure 1C). 
Importantly, the IFN-γ production by Gr-1+CD11b+ cells in the 
liver of Jα18–/– mice treated with HMGB1 was not upregulated, 
although accumulation of Gr-1+CD11b+ cells was similar to that 
in wild-type mice (Figure 1C). These findings indicate that IFN-γ 
production by Gr-1+CD11b+ cells in the liver of mice treated with 
HMGB1 is dependent on NKT cells.
Involvement of TLR2 and RAGE but not TLR4 in HMGB1-dependent 
early loss of transplanted islets. We further investigated whether HMGB1-
dependent early loss of transplanted islets is dependent on TLR2, 
TLR4, and/or RAGE, which is known to be a potential receptor of 
HMGB1 (10–14). Isolated liver MNCs from wild-type mice induced 
augmented production of IL-12 and IFN-γ in response to HMGB1 in 
vitro (Figure 2A), which were greatly reduced in Tlr2–/– and Rage–/– liver 
MNCs but not in Tlr4–/– liver MNCs, whose cytokine production levels 
were equivalent to those of wild-type mice in response to HMGB1.
To elucidate which receptor(s) for HMGB1 are actually involved 
in early loss of transplanted islets, STZ-induced diabetic Tlr2–/–, 
Tlr4–/–, or Rage–/– mice that received 200 syngenic islets were inves-
tigated for glucose levels in the serum. Interestingly, all of Tlr2–/– or 
Rage–/– mice (5 of 5) became normoglycemic, while Tlr4–/– mice 
remained hyperglycemic after transplantation, indicating that 
TLR2 and RAGE, but not TLR4, play an essential role in the early 
loss of transplanted islets (Figure 2B).
Pancreatic islet cells are a major source of HMGB1, which mediates 
IFN-γ production by NKT cells and Gr-1+CD11b+ cells. To validate 
the involvement of HMGB1 in early loss of transplanted islets, 
we carried out histological examination on islets before and 
after transplantation. HMGB1 was detected at a high level in 
cytoplasm as well as nucleus of transplanted islets as early as 
3 hours after transplantation, while HMGB1 was stained only in 
the nucleus of islets in the naive pancreas and of isolated islets 
(Figure 3A). The results suggest that HMGB1 is localized in the 
nucleus of pancreatic islets, shuttled to cytoplasm, and possibly 
secreted into the circulation soon after transplantation.
Next, we examined the amounts of HMGB1 in isolated islets 
in comparison with those in other organs, including the thymus, 
lung, spleen, liver, and pancreas, as well as of FACS-sorted liver 
MNCs, including NK, NKT, T, B, Gr-1–CD11b+, and Gr-1+CD11b+ 
cells. Currently, there are no data available with respect to the 
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tribution of HMGB1 has been reported previously (18). To our 
surprise, isolated islets contained high levels of HMGB1, which 
were 20 times more greater than in other organs or FACS-sorted 
cells tested (Figure 3B). The physiological roles of high concentra-
tions of HMGB1 in islet cells as well as their etiology are a matter 
of interest and need to be clarified in future studies.
To investigate a direct relationship between HMGB1 and islet cell 
damage, we cultured isolated mouse islets in the absence or presence 
of cytotoxic proinflammatory cytokines, including IFN-γ, TNF-α, 
and IL-1β, which are known to induce islet cell death in vitro (19) 
with elevated concentrations of HMGB1 in the culture medium (20). 
IL-10 was used as a control. Islet cell death was assessed by fluores-
cence microscopy with the use of the DNA-binding dye propidium 
iodide (PI) and Hoechst 33342 (HO 342) (19). PI, a highly polar dye 
that is impermeable to cells with preserved membranes, stains DNA 
red when membranes are damaged. HO 342 freely passes the plasma 
membrane, readily enters cells with intact membranes, and stains 
DNA blue. Thus, the nuclei of dead cells stained red by PI, while 
those of intact cells stained blue without fragmentation and con-
densation by HO 342. PI-positive islet cells were increased in num-
ber with time in the presence of cytotoxic cytokines, while those in 
the absence of cytotoxic cytokines and in the presence of the control 
cytokine remained low in number (Figure 3C). In parallel, HMGB1 
concentration in the islet cell culture medium increased with time 
in the presence of cytotoxic cytokines, while, in contrast, that in the 
absence of cytotoxic cytokines as well as in the presence of the con-
trol cytokine remained low (Figure 3C).
The above findings suggest that HMGB1 of transplanted islets 
may be released into the circulation of recipient mice in association 
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HMGB1 levels in the STZ-induced diabetic mice were elevated, with 
a peak at 24 hours, and returned to the preinjection levels by 72 hours 
after i.v. injection of STZ, while, after islet transplantation, HMGB1 
peaked at 6 hours and returned to pretransplant levels by 7 days 
(Figure 3D). The findings suggest that the first peak of the serum 
HMGB1 elevation is due to islet cell damage caused by STZ injec-
tion, which is a toxic agent to β cells of islets, while the second 
HMGB1 peak is due to the early loss of transplanted islets.
Cell types responsible for HMGB1-mediated cytokine production. We 
investigated the mechanisms of action of HMGB1 by measuring in 
vitro production of IFN-γ and IL-12 in the culture of isolated liver 
MNCs from wild-type and Jα18–/– mice in response to HMGB1, 
since IFN-γ is critical in the early islet graft loss (2) and also because 
IL-12 is essential for IFN-γ production by NKT cells (21). Isolated 
liver MNCs from wild-type mice induced augmented production 
of IL-12 and IFN-γ in response to HMGB1 in vitro (Figure 4A). 
Importantly, the amount of IL-12 and IFN-γ produced by liver 
MNCs in NKT cell–deficient Jα18–/– mice treated with HMGB1 
was greatly reduced (Figure 4A), indicating that NKT cells aug-
ment HMGB1-dependent IL-12 and IFN-γ production.
We then investigated expression of Tlr2 and Rage by quantitative 
real-time PCR in each FACS-sorted cellular population from the 
liver, including NK1.1+CD3– NK, α-GalCer/CD1d dimer+ NKT, 
CD3+ T, and CD19+ B cells; Gr-1+CD11b+CD11c– neutrophils 
(Neu); and Gr-1–CD11b+ cells, which were further divided into 
CD11c+F4/80– DCs and CD11c–F4/80+ monocytes/macrophages 
(Mo/Mφ) (Supplemental Figure 1; supplemental material available 
online with this article; doi:10.1172/JCI41360DS1). Tlr2 and Rage 
were detected at high levels on Neu (Figure 4B). DCs also expressed 
modest levels of both Tlr2 and Rage. However, Mo/Mφ expressed 
modest levels of Tlr2 but low levels of Rage, while expression of 
either Tlr2 or Rage was barely detected in other cell populations 
(NK, NKT, T, and B cells) (Figure 4B).
In order to dissect further the mechanisms of action of HMGB1, 
we investigated in vitro IL-12 and IFN-γ production in the culture 
of FACS-sorted individual cellular populations from liver MNCs 
in response to HMGB1. IL-12 was mainly produced from DCs 
rather than Neu or Mo/Mφ (Figure 4C). However, IFN-γ produc-
tion was not detected in any individual cell population among all 
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Since IL-12 was produced in vitro from DCs in response to 
HMGB1 (Figure 4C) and since NKT cell–dependent IFN-γ pro-
duction by Neu is an essential component of early loss of trans-
planted islets as shown previously (2), IL-12 and IFN-γ produc-
tion of FACS-sorted DCs, Mo/Mφ, or Neu cocultured in the 
presence of NKT cells with addition of HMGB1 was examined. 
The production of IL-12 was greatly augmented in response to 
HMGB1, especially when DCs were cocultured with NKT cells 
(Figure 4D). The production of IFN-γ became evident in the 
culture medium of DCs cocultured with NKT cells in the pres-
ence of HMGB1 (Figure 4D). The cell types responsible for the 
production of IFN-γ in response to HMGB1 in Figure 4D were 
NKT cells but not DCs, because intracellular cytokine staining 
revealed that NKT cells, but not DCs, produced IFN-γ (Figure 4E). 
It was also shown that Neu production of IFN-γ was augmented 
in the presence of NKT cells (Figure 4D).
It is known that IFN-γ production by NKT cells is largely depen-
dent on the interaction between CD40L expression on activated 
NKT cells and CD40 expression on DCs (22). Thus, we measured 
CD40 expression on DCs and Neu stimulated with HMGB1. 
CD40 surface expression was detected in both cell types in rest-
ing conditions, while upregulation of CD40 was observed in DCs 
rather than Neu in HMGB1-treated conditions (Figure 5A). Fur-
thermore, production of both IL-12 and IFN-γ mounted in vitro 
by HMGB1 stimulation was blocked by anti-CD40L antibody 
(Figure 5B), indicating that augmented IL-12 production from 
DCs and Neu and also IFN-γ production by NKT cells and Neu 
are triggered by CD40/CD40L interaction.
To confirm the data shown in Figure 5, A and B, we determined 
in vivo requirement of IL-12 and CD40-CD40L interaction in 
early loss of transplanted islets. Hyperglycemia of STZ diabetic 
mice receiving 200 syngenic islets in the liver was ameliorated by 
treatment with either anti–IL-12 or anti-CD40L antibody once at 
the time of islet transplantation, while that of mice treated with 
control antibody was not (Figure 5C). Together with the previous 
studies showing that the anti–IFN-γ treatment normalizes hyper-
glycemia (22), the results indicate that IL-12 and CD40-CD40L 
interaction together with IFN-γ actually play a crucial role in vivo 
in early loss of transplanted islets.
??????????
Among the most important findings of the present study is that 
pancreatic islets contain abundant HMGB1 compared with other 
organs and individual cell populations in the liver, the site of islet 
transplantation. Immunohistochemical staining of the pancreas 
revealed that HMGB1 is mainly stained in the nucleus of islet cells 
but not in other cell types, while HMGB1 is detected in the circu-
lation after islet cell damage. In fact, the plasma concentration of 
HMGB1 in wild-type mice was elevated and peaked at 24 hours 
after i.v. injection of STZ and returned to the preinjection level 
72 hours after STZ injection. The plasma levels of HMGB1 in dia-
betic recipient mice were elevated after islet transplantation with 
a peak at 6 hours and returned to pretransplant levels by 24 hours. 
These findings suggest that the first peak of the elevated HMGB1 
levels is caused by destruction of islet cells by a toxic agent of STZ 
specific to β cells of islets and that the second peak in recipient 
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mice after islet transplantation is related to the damage of islet 
grafts soon after transplantation. Thus, combined with in vitro 
findings of elevated concentrations of HMGB1 in the culture 
medium of isolated islets in the presence of cytotoxic cytokines, 
the plasma levels of HMGB1 may reflect the degree of islet dam-
age in the liver after transplantation. Furthermore, the treat-
ment with anti-HMGB1 antibody delayed the onset of diabetes 
in NOD mice, suggesting that HMGB1 plays a significant role in 
disease progression (23).
The above findings prompted us to determine whether HMGB1 is 
involved in the early loss of transplanted islets, which occurs within 
6 hours after islet transplantation and is an event caused by inflam-
matory cytokines, as we previously reported (2, 23). In fact, the 
hyperglycemia of islet-transplanted diabetic mice was ameliorated 
by treatment with anti-HMGB1 antibody, indicating that HMGB1 
is essentially involved in the early loss of transplanted islets.
Concerning the mechanisms of HMGB1-mediated early islet 
graft loss, 3 cell types, NKT cells, Gr-1–CD11b+CD11c+F4/80– DCs, 
and Gr-1+CD11b+ Neu, were found to be involved in the initial 
phase of early loss of transplanted islets. Among these cell types, 
the primary cellular targets of HMGB1 does not seem to be NKT 
cells, since the receptors for HMGB1 (10–14) TLR2 and RAGE but 
not TLR4 (Figure 2B) are expressed on DCs, Mo/Mφ, and Neu, but 
not on NKT cells (Figure 4B). IL-12, which is essential for NKT 
cell–dependent production of IFN-γ, was mainly produced by 
DCs after HMGB1 stimulation (Figure 4C). Thus, it is likely that 
the first target for HMGB1 is DCs, which in turn activate NKT 
cells. Then, activated NKT cells themselves produce IFN-γ and also 
stimulate Neu to produce IFN-γ (Figure 4D), which is an essential 
component of HMGB1-mediated early loss of transplanted islets.
Thus, the present study unveils a role of DCs in HMGB1-
dependent IFN-γ production by NKT cells. DCs stimulated with 
HMGB1 in vitro upregulate their CD40 expression and produce 
IL-12, which is markedly augmented in the presence of NKT cells, 
facilitating IFN-γ production by NKT cells and subsequently that 
of Neu. The requirement of CD40-CD40L interaction and IL-12 
is confirmed by the fact that anti-CD40L and anti–IL-12 antibod-
ies prevented early loss of transplanted islets, leading to amelio-
ration of hyperglycemia of islet-transplanted diabetic recipient 
mice, while the corresponding control antibody did not. Thus, 
the uncovered pathways involved in the early loss of transplanted 
islets in the present study afford further new targets for interven-
tion to improve the efficiency of islet transplantation.
TLR2, TLR4, and RAGE as potential receptors for HMGB1 (10–14) 
are expressed mainly on DCs, Mo/Mφ, and Neu (Figure 4B). How-
ever, in vitro and in vivo experiments revealed that TLR2 and RAGE 
but not TLR4 are involved in the early loss of transplanted islets 
(Figure 2B). It has been reported that HMGB1-mediated biological 
effects and usage of their receptors are different in the experimen-
tal models. For example, TLR4, but not TLR2 or RAGE, has been 
shown to be an HMGB1 receptor in hepatic reperfusion injury 
(24). Similarly, HMGB1 signaling through TLR2 and TLR4 but 
not RAGE contributes to LPS-induced inflammation (11). In the 
case of SLE, HMGB1 present in DNA-containing immune com-
plexes triggers activation of autoreactive B cells and plasmacytoid 
DCs through RAGE (17). These differences in HMGB1-mediated 
effects might be due to the presence, in different systems, of cell 
types with distinctly different HMGB1 receptor expression pro-
files, and also due to the formation of complexes of HMGB1 with 
different molecules under varying disease conditions.
Concerning the form of HMGB1, HMGB1 acquires and/or aug-
ments inflammatory effects when it binds to other inflammatory 
molecules, such as IL-1β, the TLR4 ligand LPS, the TLR9 ligand 
CpG-ODN, or the TLR1-TLR2 ligand Pam3CSK (14–17). Recent 
studies on HMGB1-deficient mice also showed that HMGB pro-
teins function as universal sentinels for nucleic acids (25). How-
ever, in the present studies, it still remains unsolved what types of 
molecules interact with HMGB1 protein to mediate its function.
Chen et al. (26) have reported that the direct effects of RAGE on 
conventional T cell functions resulted in the prolongation of syn-
geneic and allogeneic islet graft transplanted in the subcapsular 
space of kidney, in that anti-CD3/CD28–induced T cell prolifera-
tion, mixed lymphocyte reaction, and T cell production of IL-10, 
IL-5, and TNF-α but not IFN-γ were inhibited in RAGE-deficient 
mice and mice receiving RAGE inhibitor. Since no conventional T 
cells were involved in the early loss of islet transplanted in the liver, 
and also because IFN-γ, but not IL-10 nor IL-5, is a major player in 
the early islet loss, the mechanisms observed in the present studies 
are different from those described by Chen et al. (26).
Concerning the potential sites for islet transplantation — includ-
ing the liver, renal subcapsular space, omental pouch, abdominal 
cavity, intramuscular site, subcutaneum — the liver is currently the 
only site where insulin independence in patients with type 1 diabe-
tes mellitus can be achieved with clinical islet transplantation, as 
reported by Shapiro et al. (1). Although we do not have any data on 
islet transplantation at non–NKT cell–dense sites, the NKT cell–
mediated early loss of islets can occur at any tissue, as it has been 
demonstrated in the allogeneic heart transplantation model that 
NKT cells migrate immediately into non–NKT cell–dense trans-
plantation sites, where CXCL16, the ligand for chemokine recep-
tor CXCR6 selectively expressed on NKT cells, is expressed (27).
Taken collectively, the findings in the present study shed light on 
the mechanisms involved in the early loss of transplanted islets as 
follows. First, islet cells themselves are a major source of HMGB1, 
which is released from transplanted islets. Since the plasma levels 
of HMGB1 reflect the degree of islet damage, HMGB1 could be a 
marker to predict rejection of transplanted islets. Second, HMGB1 
stimulates production of inflammatory cytokines including IL-12 
and IFN-γ in concert with DCs, NKT cells, and Neu in the liver 
receiving islets. Third, these inflammatory cytokines accelerated 
the injuries of transplanted islets. Thus, a vicious cycle harmful 
to transplanted islets is now unveiled. Therefore, each pathway 
involved in the early loss of transplanted islets revealed by the 
present study is a potential target for intervention to improve effi-
ciency of islet transplantation.
???????
Mice. C57BL/6 mice were purchased from Charles River Japan Inc. or 
CLEA Japan Inc. Jα18-deficient mice were generated previously (28) and 
backcrossed more than10 times to C57BL/6 mice. Rage–/– mice (29) were 
described previously. Tlr2–/– and Tlr4–/– mice were provided by Shizuo Akira 
(Osaka University, Osaka, Japan). Mice were kept under specific patho-
gen–free conditions and used at 8–16 weeks of age. All experiments were in 
accordance with protocols approved by the Animal Care and Use Commit-
tee of Fukuoka University and RIKEN.
Islet isolation and transplantation. Islets were isolated (30, 31) and trans-
planted into the liver via the portal vein (32) of STZ-induced (180 mg/kg; 
Sigma-Aldrich) diabetic mice at 3 days after the injection of STZ. The non-
fasting plasma glucose levels of mice were measured using a Beckman glu-
cose analyzer (Beckman Japan).
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Immunohistochemistry. The pancreas of naive mice, isolated islets, and 
the liver of transplant recipients were fixed in 10% formaldehyde solution, 
processed, and embedded in paraffin. The sections were stained immuno-
histochemically with anti-mouse insulin antibody (Novocastra) and rabbit 
anti-bovine HMGB1 antibody (Shino-Test Co.) by a streptavidin-biotin-
peroxidase complex method (33).
HMGB1 and cytokine measurement. HMGB1 levels in mouse serum and 
in the culture medium of isolated islets was measured with an ELISA kit 
(Shino-Test Co.) (34). IFN-γ concentrations in the culture supernatant 
of liver MNCs were determined by FACS with cytometric beads assay 
(CBA) (BD Biosciences). IL-12 concentration in the medium was mea-
sured by ELISA (Endogen).
For measurement of tissue concentration of HMGB1, individual tis-
sues (1–2 mg wet weight/organ), isolated islets (200 total), and FACS-
sorted cells (2 × 105 to 6 × 105) of each population in the liver of mice 
were sonicated in PBS. Then, the resulting tissues were treated as report-
ed by Sanders (35) in which perchloric acid (HClO4) was added to the 
homogenates with a concentration of 0.75 M. The content of HMGB1 in 
the solution was measured with ELISA after the adjustment of pH to 7.0 
as well as the appropriate dilution with PBS containing 1% bovine calf 
serum. The sonicated tissues were also used for measuring DNA content 
with a Wako assay kit.
Reagents. Bovine HMGB1 was purchased from Shino-Test Co. Bovine 
HMGB1 was extracted from the bovine thymus and further purified 
by CM-Sephadex C25 ion column chromatography according to the 
method described by Sanders (35). The biological activity of purified 
HMGB1 was reported elsewhere (36). Anti-HMGB1 antibody was pur-
chased from Shino-Test Co. This is a polyclonal antibody made by 
immunizing chicken with purified bovine HMGB1, and the neutral-
izing effect of the anti-HMGB1 antibody was reported previously (37, 
38). Goat anti-mouse IL-12 antibodies and rabbit anti-mouse CD40L 
antibody were purchased from BD Biosciences and Sigma-Aldrich, 
respectively. Recombinant mouse IFN-γ, TNF-α, IL-1β, and IL-10 were 
purchased from Sigma-Aldrich.
Flow cytometry. Antibodies used for flow cytometric analysis were as fol-
lows: anti-mouse FcRγII/III (2.4G2), FITC- or Pacific blue–conjugated 
anti-CD3ε (145-2C11), FITC- or PerCP-Cy5.5-conjugated anti-CD11b 
(M1/70), allophycocyanin-conjugated (APC-conjugated) anti–IFN-γ 
(XMG1.2), peridinin–chlorophyll protein– (PerCP-) or FITC-conjugated 
anti-Gr-1 (RB6-8C5), PE-conjugated NK1.1 (PK136), PE-Cy7–conjugat-
ed CD19 (1D3), biotinylated anti-CD11c (N418), APC-Cy7–conjugated 
avidin, APC-conjugated anti-F4/80 (BM8) (BD Biosciences or eBiosci-
ence). PE- or APC-labeled α-GalCer–loaded CD1d dimer was prepared 
as described (39). Intracellular cytokine staining was performed as previ-
ously described (39). Flow cytometry was performed using a FACSCalibur 
and FACSAria (BD) with FlowJo software (Tree Star). The purity of sorted 
cells was usually greater than 99%.
Cell preparation and culture. Liver MNCs were prepared as described pre-
viously (40). For in vitro culture, liver MNCs and those of FACS-sorted 
cells were cultured in RPMI medium (Sigma-Aldrich) supplemented with 
5% fetal bovine serum (Biosource) and 100 µg/ml kanamycin (Meiji Seika) 
and isolated islets in DMEM medium (Nissui) supplemented with 2% BSA 
(Sigma-Aldrich) and 100 µg/ml kanamysin in a CO2 incubator (95% air 
plus 5% CO2) at 24°C or 37°C.
Quantitative real-time PCR. Total RNA was isolated from FACS-purified 
cell populations using TRIZOL reagent (Invitrogen). cDNA was prepared 
by Superscript III RNase H– Reverse Transcriptase with random hexam-
ers (Invitrogen). Quantitative real-time PCR was performed with SYBR 
GreenER qPCR SuperMix (Invitrogen) for ABI PRISM 7900HT (Applied 
Biosystems). Total mRNA from cells (2 × 103) was used as templates to 
analyze expression levels of Tlr2, Rage, or Hprt. Gene-specific primer 
sequences were as follows: Tlr2-fw, GGGGCTTCACTTCTCTGCTT, Tlr2-rv, 
AGCATCCTCTGAGATTTGACG; Rage-fw, 5′-GTGTCGGGCAAC-
TAACAGG-3′, Rage-rv, 5′-CTGGCTTCCCAGGAATCTG-3′; Hprt-fw, 5′-
TCCTCCTCAGACCGCTTTT-3′, Hprt-rv, 5′-CCTGGTTCATCATCGCTA-
ATC-3′. Quantitative analysis was performed by the ΔΔCt method by using 
Hprt as an internal control.
Statistics. The statistical significance of differences was determined by 
1-tailed Student’s t test. Values were expressed as mean ± SD from inde-
pendent experiments. Any difference with a P value less than 0.05 was 
considered significant.
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